Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Terry Chrisomalis Investing Group Leader Follow Summary Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phase 3 SUPRAME for 2nd-line melanoma, with final PFS data expected in H1 2027. Positive phase 1b data [56% cORR, 6.1m PFS] and expansion into metastatic uveal melanoma support label expansion and broader PRAME pipeline ambitions. The company raised $150M to extend cash runway beyond 12 months but faces clinical, regulatory, and competitive risks in melanoma and PRAME-driven indications. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Jack Tamrong/iStock via Getty Images The last time I wrote about Immatics N.V. ( IMTX ), it was with a Seeking Alpha article entitled " Immatics: Additional Gains Possible in Q4 of 2023 With Data Update of IMA203 ." With This article was written by Terry Chrisomalis 15.13K Followers Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.